By Jonathan D. Rockoff
The head of Eli Lilly’s research into Alzheimer’s disease, schizophrenia and other neurological diseases is unexpectedly leaving the company.
David Bredt’s last day at the drug maker is Feb. 25, a company spokeswoman says. He had joined Lilly in 2004.
Fellow industry drug researchers expressed surprise at the news, especially since Bredt had given no indication of his plans at recent events.
His departure comes after Lilly experienced a number of setbacks in its Alzheimer’s research, in particular. Most notably, the company halted development of an experimental Alzheimer’s drug called semagacestat last August, after studies showed it was worsening patients’ conditions.
via blogs.wsj.com
1 comment:
Post a Comment